Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Insmed has strong biotech catalysts: Q2 revenue was $425.5M, BRINSUPRI revenue grew 49% sequentially to $309.2M, 2026 BRINSUPRI guidance was raised to $1.25B-$1.40B, TPIP data were favorable, and the Q2 loss of $0.52 beat the $0.69 consensus loss.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Cash Burn ⢠Elevated Leverage INSM shows strong revenue growth, margins, and liquidity, but persistent losses, cash burn, leverage, dilution, and premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Mild bearish trend ⢠Critical support zone ⢠Reclaim resistance Support Level: $118.50â$120.00 Resistance Level: $124.00â$126.00 INSM is bearish over the last month, with $118.50â$120.00 support critical; a break below raises downside risk, while reclaiming $124â$126 would improve momentum.
Sentiment & News
Key News Insights: ⢠Japan Approval ⢠Sales Outlook ⢠Pipeline Progress Insmed's Japan approval for BRINSUPRI, raised peak-sales outlook, and advancing respiratory pipeline reinforce growth potential despite forecast-execution risks.
AI Summary
Insmed has transitioned into a high-growth commercial respiratory company as BRINSUPRI's launch rapidly scales revenue, but its premium valuation now requires sustained uptake, declining cash burn, and eventual profitabilityânot merely positive launch data; investors should monitor BRINSUPRI guidance delivery and payer persistence while treating TPIP as option value rather than guaranteed sales.
Description
Insmed is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases, and it markets ARIKAYCE for adult Mycobacterium avium complex lung disease as part of a combination antibacterial regimen. The companyâs pipeline includes Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor in development for bronchiectasis and other neutrophil-mediated conditions, and an inhaled treprostinil palmitil prodrug being studied for pulmonary arterial hypertension and other rare pulmonary disorders.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 7 | Aug 14 | INSM | Insmed Incorporated | Insmed has strong biotech catalysts: Q2 revenue was $425.5M, BRINSUPRI revenue grew 49% sequentially to $309.2M, 2026 BRINSUPRI guidance was raised to $1.25B-$1.40B, TPIP data were favorable, and the Q2 loss of $0.52 beat the $0.69 consensus loss. | Closed | -5.6% |
| Jul 8 | Jul 15 | INSM | Insmed Incorporated | Strong healthcare momentum with concrete clinical and commercial support: shares rose 22.7% over 21 trading days, Q1 2026 revenue was $306.0M, ENCORE met its primary and key secondary endpoints, and pipeline activity includes TPIP Phase 3 initiation. | Closed | -5.8% |
| Apr 1 | Apr 8 | INSM | Insmed Incorporated | Fresh positive Phase 3 ENCORE topline (3/23) and strong 2026 revenue guidance (BRINSUPRI âĽ$1B, ARIKAYCE $450â470M) have driven ~9.8% 21-day ROC and price ~13% above the 21-day SMA. With Phase 2b CEDAR topline due in Q2 2026, the stock is a high-risk but well-defined event-driven long for the coming days. | Closed | -2.8% |
| Nov 24 | Dec 1 | INSM | Insmed Incorporated | Insmed (INSM) is supported by FDA approvals, strong Q3 revenue growth (+22% ARIKAYCEÂŽ), bullish technical momentum (+24.5% over 21 days), and raised guidance reflecting commercial traction. Despite continuing losses and high valuation, ongoing pipeline catalysts and significant liquidity underpin a moderate short-term upside case. | Closed | +2.2% |